Program Disclosure

- This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and the Chronic Liver Disease Foundation. Purdue University School of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians.

- This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure (cont.)

• **Credit Designation** – Purdue University College of Pharmacy designates this live activity for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• **Faculty Disclosure Statement** - All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

• **Nursing Accreditation Statement** - Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This program has been approved for .5 contact hours.

• **Pharmacist Accreditation Statement** - Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-15-007-L01-P, .5 contact hours (.5 CEU).
**Faculty, Staff and Reviewer Disclosure Statement**

- **Medical Writer: Lisa Pedicone, PhD** - No Relevant Relationships

- All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

“All additional planning committee members, Chronic Liver Disease Foundation and Purdue University College of Pharmacy staff have no relationships to disclose.”
Educational Objectives

• Discuss the natural history and complications of cirrhosis including management options

• Review data on the screening, diagnosis and management of chronic liver disease

• Describe the importance of linking patients with chronic liver disease into specialty care
Case 1

• Paul is a 62 year old black man who presents to the ER with severe abdominal pain.
• PMHx: “liver problem” years ago when drinking
  – Developed ascites but resolved with abstinence
• Exam: Diffusely tender abdomen with some guarding
• Labs:
  – CBC: WBC 7.2, Hb 10.1, Plts 71
  – CMP: Alb 3.4, TB 1.2, AST 32, ALT 25, AP 251, Cr 1.2
  – Viral hepatitis screen: negative
• CT with large heterogeneous mass
Discussion

1. Does Paul have cirrhosis?
   – What do you suspect is the reason for his pain?

2. How do you diagnose cirrhosis?
   – Biopsy
   – Imaging
   – Non-invasive markers? And for which etiologies?
   – Transient elastography?

3. What would you do next?
Compensated Cirrhosis May Be Difficult to Recognize

- Asymptomatic (compensated)
  - Subtle clues may be overlooked
    - Thrombocytopenia
    - Muscle wasting
    - AST>ALT without alcohol consumption
    - Liver enzymes may not be abnormal
  - Etiology may be remote
    - Prior alcohol use
    - Uncontrolled DM and obesity
- Decompensated (Symptomatic)
  - Portal hypertension: ascites, OHE, variceal bleeding
  - Hepatic failure: Jaundice, Coagulopathy

Diagnosis of Cirrhosis and Chronic Liver Failure

**History** --or-- **Physical Examination** --or-- **Laboratory Studies** --or-- **Radiographic Studies**

- Physical examination findings consistent with liver disease or high suspicion for chronic liver disease
- Confirm history via signs and symptoms of chronic liver disease and positive risk factors
- Confirm history via signs and symptoms of chronic liver disease and positive risk factors and screen for hallmark physical examination findings

Obtain liver panel*, CBC with platelets, PT/INR, and targeted serologic studies to determine etiology

Obtain abdominal imaging for confirmation of cirrhosis and HCC screening

Refer for possible liver biopsy if diagnosis of cirrhosis is uncertain, as well as possible determination of etiology via histology if not readily determinable through serologic testing and if potential benefit outweighs risk of procedure

*Tests typically include ALT, AST, alkaline phosphatase, and \(-\)-glutamyltransferase, total, direct and indirect serum bilirubin, and serum albumin. Adapted from Heidelbaugh JJ, Bruderly M. *Am Fam Physician* 2006;74:756-762.
Non-Invasive Markers

- Indirect biomarkers
  - APRI, FIB4 etc

- Direct biomarkers
  - Fibrotest, Fibrosure, etc

- Transient Elastography

- Clinically obvious cirrhosis does not require confirmation
• The prevalence of cirrhosis, both worldwide and in the US, is unknown\(^1\)
  
  – Cirrhosis is an outcome of a variety of causes; underlying cause is commonly used for surveillance purposes\(^2\)
  
  – Compensated cirrhosis often goes undetected for prolonged periods of time\(^1\)

• Experts estimate that 5.5 million people in the United States have cirrhosis\(^3\)

Progressive Increase in Incidence of HCV-Related Cirrhosis and HCC in US

Annual Prevalence Rates Between 1996 and 2006 Among HCV-Infected Veterans

El-Serag HB. *Gastroenterology* 2012;142:1264–1273.
Liver Cancer Projected to Be the 3rd Leading Cause of Cancer-Related Death by 2030

“Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver and Pancreas Cancers in the United States.”

- Cancer incidence/deaths projected for 2020 and 2030
- Breast, prostate, and lung cancers remain top cancer diagnoses
- Lung cancer is projected to remain top cancer killer
  - Pancreas and **liver cancers** projected to surpass breast, prostate, and colorectal cancers to become the 2nd and 3rd leading causes of cancer-related death
Early Recognition Allows Preventative Measures

- HCC screening
- Screening for varices
- Recognition of encephalopathy
- Recognition of ascites
- Life style and nutrition counseling
- Early intervention when decompensation first recognized
HCC Screening

• HCC detected after the onset of symptoms has a very poor prognosis
  – With 0-10% survival at 5 years
• Early recognition can improve outcomes
  – Resection or liver transplantation
  – 5-year disease-free survival of greater than 50%
• Screening with Ultrasound recommended at 6 month intervals in all individuals with cirrhosis
• MUST RECOGNIZE CIRRHOSIS
HCC Diagnostic Algorithm

Liver nodule

- < 1 cm
  - Repeat US at 3 months
    - Growing/changing character
      - Investigate according to size
    - Stable
- > 1 cm
  - 4-phase MDCT/ dynamic contrast enhanced MRI
    - Arterial hypervascularity AND venous or delayed phase washout
      - Other contrast Enhanced study (CT or MRI)
        - Yes
          - Arterial hypervascularity AND venous or delayed phase washout
            - Yes
              - HCC
            - No
              - Biopsy
        - No
          - Biopsy

Tim is a 56 year old white man with HCV cirrhosis complicated by ascites and non-bleeding varices. He is listed for transplantation with a MELD of 17.

His wife calls his coordinator because Tim has been sleeping all day.

The coordinator advises her to take Tim to the nearest ER.
How would you explain Tim’s symptoms?

• Primary complications of cirrhosis include:
  – Ascites
  – Jaundice
  – Variceal hemorrhage
  – **Hepatic encephalopathy**

• Other complications that can occur include:
  – Hepatocellular carcinoma
  – Spontaneous bacterial peritonitis
  – Hepatic hydrothorax
  – Hepatorenal syndrome
  – Portopulmonary hypertension
  – Portal vein thrombosis
  – Hepatopulmonary syndrome

Overt Hepatic Encephalopathy (OHE)

- Overt hepatic encephalopathy (OHE) occurs in:
  - 30% to 45% of cirrhotic patients
  - 10% to 50% of patients with TIPS

- Covert hepatic encephalopathy (CHE) affects approximately 20% to 60% of patients with liver disease
  - Has been called subclinical encephalopathy or minimal encephalopathy (MHE) in the past

TIPS = transjugular intrahepatic portosystemic shunt.
Mullen KD, Prakash RK. *Clin Liver Dis* 2012;16:91-93,
Diagnosis of OHE

- Clinical recognition of the distinctive neurologic features of HE
- Knowledge that underlying cirrhosis is present
- Exclusion of other etiologies of neurologic and/or metabolic abnormalities
- Identification of precipitating factors
- Grading the severity

Adapted from:
**Neurologic Manifestations of OHE**

<table>
<thead>
<tr>
<th>Common</th>
<th>Less Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Confusion or coma</td>
<td>• Cognitive deficits detected by special testing</td>
</tr>
<tr>
<td>• Asterixis</td>
<td>• Babinski sign</td>
</tr>
<tr>
<td>• Loss of fine motor skills</td>
<td>• Slow, monotonous speech</td>
</tr>
<tr>
<td>• Hyper-reflexia</td>
<td>• Extrapyramidal-type movement disorders</td>
</tr>
</tbody>
</table>


*Seizures seen primarily in type A HE.*
Other Causes of Altered Mental Status*

- Intracranial hematomas
- Thyroid dysfunction
- Hypoglycemia
- Hypoxia
- Hypercapnia
- Drug intoxication
- Hypoglycemia
- Hyperglycemia
- Acidosis
- Encephalitis
- Severe sepsis‡
- Uremia

*Most entities can be diagnosed by brain imaging or laboratory tests.
†Severe sepsis can cause encephalopathy or precipitate HE.
Characterization of HE Stages

Categorization is often arbitrary and varies between raters

Simple Clinical Diagnosis

Worsening cognitive dysfunction

West Haven Criteria

<table>
<thead>
<tr>
<th>Grade</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No abnormalities detected</td>
</tr>
<tr>
<td>I</td>
<td>Trivial lack of awareness; Euphoria or anxiety; short attention span; Impairment of addition or subtraction</td>
</tr>
<tr>
<td>II</td>
<td>Lethargy or apathy, Disorientation for time, Obvious personality change, Inappropriate behavior</td>
</tr>
<tr>
<td>III</td>
<td>Somnolence to semi-stupor, Responsive to stimuli, Confused, Gross disorientation, Bizarre behavior</td>
</tr>
<tr>
<td>IV</td>
<td>Coma, unable to test mental state</td>
</tr>
</tbody>
</table>

One’s clinical impression is the main guide to diagnosing hepatic encephalopathy (HE).

A normal or modestly elevated blood ammonia level does not rule out a diagnosis of HE.

Blood ammonia testing may be helpful if there is no clear evidence of underlying chronic liver disease.

- An increased blood ammonia level may have prognostic value (e.g., acute liver failure) or may be the basis for further evaluation for uncommon metabolic disorders (e.g., urea cycle disorders).
How would you manage Tim?
Proposed Algorithm for Inpatient OHE Management

- Patient with possible OHE
  - Confirm that it is HE: Yes
    - Initiate empiric treatment for HE; Search for precipitating factor
      - Precipitating factors found
        - Treatment directed to the precipitating factor
      - Precipitating factors not found
        - Admit to ICU for grade ≥ 3 HE
        - Continue HE therapy with lactulose and rifaximin
  - No HE: Other causes of altered mental status

Evaluate for liver transplant

Adapted from Bajaj JS. *Aliment Pharmacol Ther* 2010;31:537-547 and Prakash R, Mullen KD. *Nat Rev Gastroenterol Hepatol* 2010;7:515-525
Treatment Approach for Acute Overt Hepatic Encephalopathy

• Precipitating factors:
  – GI bleeding
  – Infection
  – Sedating medications
  – Electrolyte abnormalities
  – Constipation
  – Renal Failure
Treatment Approach for Acute Overt Hepatic Encephalopathy: Lactulose + Rifaximin vs. Lactulose


- Treatment was given through nasogastric tube and continued until recovery of HE or a maximum of 10 days.
- Hospital stay was shorter with lactulose + rifaximin than with lactulose + placebo (5.8±3.4 vs. 8.2±4.6 days, *P*=0.001)
## General supportive and nutritional interventions

<table>
<thead>
<tr>
<th>General supportive care</th>
<th>Nutritional support</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Fall precautions in disoriented patients</td>
<td>• Regular protein diets are recommended</td>
</tr>
<tr>
<td>• Prevention of infections--changing IV lines, prevent aspiration pneumonia, isolation</td>
<td>• Consider addition of branched-chain amino acids (valine, leucine, and isoleucine) and zinc; consider eliminating wheat and milk proteins</td>
</tr>
</tbody>
</table>
Outpatient Management after an Episode of OHE

• Treatment goals
  – Prevention of recurrent episodes of HE
  – Improvement of daily functioning
  – Evaluation for liver transplant

Bajaj JS. *Aliment Pharmacol Ther.* 2010;31:537-547.
Prophylactic Treatment of HE

- Treating patients with covert HE to prevent development of a first episode is referred to as **primary prophylaxis** of HE

- Preventing recurrence of HE in patients who had a previous episode of HE is referred to as **secondary prophylaxis** of HE
US Hospital Discharges Associated with Hepatic Encephalopathy* Are Increasing

HE = hepatic encephalopathy; ICD = International Classification of Diseases.
*Data calculated using ICD-9-CM codes 291.2 (alcoholic dementia, not elsewhere classified), 348.30 (encephalopathy, not otherwise specified), and 572.2 (hepatic coma). †Includes all listed discharge diagnoses.
Hospital Readmissions Among Patients with Decompensated Cirrhosis are Common

- Retrospective study of 402 patients from an academic transplant center
- Follow-up time censored at death, elective admissions such as transplant or post-procedure observation, or the date of last clinic note; median follow-up was 203 days
- Population included cirrhotic patients hospitalized for ascites, spontaneous bacterial peritonitis, renal failure, hepatic encephalopathy, or variceal hemorrhage
- Median time to first readmission was 67 days
- Median number of readmissions was 2 (range 0-40); overall rate was 3 hospitalizations/person-years

Overt HE Is Associated with a Poor Prognosis

- <50% survival at 1 year after diagnosis of HE; <25% survival at 3 years

• Tim’s OHE is well controlled on medical therapy. He returns after his hospitalization for follow-up to pre-transplant clinic.

• On review on his medication list his MD sees that he is on a beta-blocker as primary prophylaxis.

• Would you continue this medication?
• Non-selective beta-blockers (NSBBs) prevent portal hypertensive bleeding in patients with cirrhosis.

• But studies suggest NSBB use is associated with decreased survival in patients with refractory ascites.
  – NSBBs may reduce perfusion of vital organs
NSBBs Increase AKI

- Nested case-control of liver transplant waitlist registrants at Mayo clinic
  - Cases developed AKI (2-3 fold increase in serum Cr)
  - Matched by MELD-Na score, age at registration, baseline creatinine, and follow-up duration

- Impact of NSBB on AKI incidence was different according to the presence of ascites:
  - NSBB use with ascites was associated with development of AKI (hazard ratio [HR], 2.79; 95% confidence interval [CI], 1.40-5.54),
  - Without ascites, NSBB was protected (HR, 0.19; 95% CI, 0.06-0.60)
Conclusions

- Cirrhosis can be asymptomatic
- Screening and surveillance of life threatening complications can allow early recognition and preventative strategies
- Individuals with symptomatic cirrhosis and liver cancer should be considered for liver transplantation
  - Linkage to experienced providers is instrumental